MX2017013623A - Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas. - Google Patents

Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas.

Info

Publication number
MX2017013623A
MX2017013623A MX2017013623A MX2017013623A MX2017013623A MX 2017013623 A MX2017013623 A MX 2017013623A MX 2017013623 A MX2017013623 A MX 2017013623A MX 2017013623 A MX2017013623 A MX 2017013623A MX 2017013623 A MX2017013623 A MX 2017013623A
Authority
MX
Mexico
Prior art keywords
methods
compositions
detection
myeloproliferative diseases
calr mutations
Prior art date
Application number
MX2017013623A
Other languages
English (en)
Inventor
Wang Yongbao
Jones Daniel
Original Assignee
Quest Diagnostics Invest Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quest Diagnostics Invest Inc filed Critical Quest Diagnostics Invest Inc
Publication of MX2017013623A publication Critical patent/MX2017013623A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se proveen aquí­ métodos y composiciones para la detección de mutaciones de lí­nea germinal de supresión en marco del gen CALR. Tambión se proveen métodos para determinar el pronóstico de enfermedades mieloproliferativas y la probabilidad de desarrollar mutaciones somáticas en genes implicados en la ruta JAK-STAT.
MX2017013623A 2015-04-23 2016-04-22 Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas. MX2017013623A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562151742P 2015-04-23 2015-04-23
PCT/US2016/028877 WO2016172505A2 (en) 2015-04-23 2016-04-22 Methods and compositions for the detection of calr mutations in myeloproliferative diseases

Publications (1)

Publication Number Publication Date
MX2017013623A true MX2017013623A (es) 2018-07-06

Family

ID=57144325

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017013623A MX2017013623A (es) 2015-04-23 2016-04-22 Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas.
MX2022000176A MX2022000176A (es) 2015-04-23 2017-10-23 Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022000176A MX2022000176A (es) 2015-04-23 2017-10-23 Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas.

Country Status (8)

Country Link
US (3) US10519509B2 (es)
EP (1) EP3286336A4 (es)
CN (1) CN107949643A (es)
BR (1) BR112017022779B1 (es)
CA (1) CA2983820A1 (es)
HK (1) HK1254254A1 (es)
MX (2) MX2017013623A (es)
WO (1) WO2016172505A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190374611A1 (en) * 2017-01-18 2019-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders
CN107164474B (zh) * 2017-05-22 2020-09-04 复旦大学附属华山医院 一种检测calr基因2型突变的引物组合物及试剂盒
CN107679366A (zh) * 2017-08-30 2018-02-09 武汉古奥基因科技有限公司 一种基因组变异数据的计算方法
US20220282314A1 (en) * 2019-08-30 2022-09-08 Toyo Kohan Co., Ltd. Kit for evaluating a gene mutation related to myeloproliferative neoplasms
CN113764044B (zh) * 2021-08-31 2023-07-21 华南理工大学 一种构建骨髓增生异常综合征进展基因预测模型的方法
CN115141886B (zh) * 2022-06-28 2023-06-06 厦门艾德生物医药科技股份有限公司 一种基于高通量测序的髓系白血病基因突变检测的探针引物组及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2877013A1 (fr) 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US8841074B2 (en) 2009-12-04 2014-09-23 Quest Diagnostics Investments Incorporated MPL mutations in JAK2 V617F negative patients with myeloproliferative disease
EP3339318A1 (en) 2013-09-16 2018-06-27 CeMM - Forschungszentrum für Molekulare Medizin GmbH Mutant calreticulin for the diagnosis of myeloid malignancies

Also Published As

Publication number Publication date
US10519509B2 (en) 2019-12-31
MX2022000176A (es) 2022-02-21
BR112017022779A2 (pt) 2018-07-17
EP3286336A4 (en) 2018-11-14
CA2983820A1 (en) 2016-10-27
BR112017022779B1 (pt) 2024-04-30
HK1254254A1 (zh) 2019-07-12
EP3286336A2 (en) 2018-02-28
US20160312303A1 (en) 2016-10-27
US20200165688A1 (en) 2020-05-28
WO2016172505A2 (en) 2016-10-27
WO2016172505A3 (en) 2016-12-08
CN107949643A (zh) 2018-04-20
US20220364180A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
MX2022000176A (es) Metodos y composiciones para la deteccion de mutaciones de calr en enfermedades mieloproliferativas.
CY1124886T1 (el) Χιμαιρικοι υποδοχεις αντιγονου bcma
EP3704640A4 (en) PREDICTION OF CANCER-RELATED PATHOGENIC EFFECTS OF SOMATIC MUTATIONS USING DEEP LEARNING METHODS
EP3322815A4 (en) Compositions and methods for detection of genetic deafness gene mutation
PH12016502162A1 (en) Multiplex gene editing in swine
EP3143163A4 (en) Gene mutations and copy number alterations of egfr, kras and met
MX2018009750A (es) Composiciones potenciadoras de vcn y métodos para su uso.
MA41044A (fr) Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EA201791243A1 (ru) Лечение пузырчатки
MX2017006694A (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
PH12016502555A1 (en) Methods of preparing substituted nucleotide analogs
IL271301A (en) Methods and systems for determining somatic mutation clones
EP4084806A4 (en) NOVEL ANUCLEATED CELLS FOR DRUG DELIVERY AND METHODS OF USE
MX369623B (es) Compuestos biciclicos fusionados para el tratamiento de enfermedades.
GB202109153D0 (en) Ancestry-specific genetic risk scores
GB202000014D0 (en) DDX24 gene mutation and use thereof
MX2018000395A (es) Proteinas y composiciones inmunizantes que contienen proteinas de klebsiella y metodos de uso.
MX2021000899A (es) Composiciones y metodos para determinar el pronostico de cancer de endometrio.
EP3110422A4 (en) Compositions and methods for the delivery of therapeutics
IL282752A (en) Methods for altering gene expression for genetic disorders
IL247752A0 (en) Compositions and methods for modulating gene expression for site-directed mutagenesis
IL269339A (en) Methods of using genetic markers associated with endometriosis
EP3847182A4 (en) Methods of using genetic markers associated with endometriosis
EP3881325A4 (en) METHODS FOR IDENTIFYING GENETIC VARIANTS
EP3121290A4 (en) Prognosis method of autoimmune diseases by genotyping genetic variations of the vasoactive intestinal peptide